Evidence-based guidelines for the diagnosis and management of Idiopathic Pulmonary
Fibrosis (IPF) were published in 2011 (1). Four years later, the same four sponsoring …

Background: This document updates the American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …

Guidelines for the clinical management of idiopathic pulmonary fibrosis (IPF) have advanced
from being consensus based in 2000 to evidence based in 2011 (1, 2). The first evidence …

The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be
approximately 3 years from the time of diagnosis, underscoring the lack of effective medical …

Idiopathic pulmonary fibrosis (IPF) is increasingly recog-nised as a well-known clinical and
highly complex entity associated with poor prognosis and a median survival of 3–5 yrs after …

Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a
distinct form of interstitial lung disease of unknown etiology that is limited to the lung; it is …

The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …

Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly
progressive course and fatal outcome. Guidelines summarizing the current evidence and …